Benchmark GlaxoSmithKline Plc Performance against Key Rivals

LYON, France--(Business Wire)--Reportlinker.com announces that a new market research reportrelated to the Pharmaceutical industry industry is available in itscatalogue. GlaxoSmithKline plc company profile To order that report: www.reportlinker.com/p064471/GlaxoSmithKline-plc-PharmaVitae-Profile.html

(Due to its length, this URL may need to be copied/pasted intoyour Internet browser's address field. Remove the extra space if oneexists.) Introduction This analysis examines the historical and forecast performance forGSK in the ethical pharmaceutical sector. The profile encompassesglobal company strategy, portfolio and pipeline analysis andassessment of financial performance, with 1-6 year sales forecasts forkey drugs. An interactive forecasting and analysis tool providescontinually updated quantitative and qualitative information. Scope Highlights Reasons to Purchase Benchmark GlaxoSmithKline's performance against key rivals in theethical pharmaceutical sectorAnalyze the factors that will underscorea forecast ethical pharmaceutical sales CAGR of -2.1% forGlaxoSmithKline over 2006-12Assess the generic threat faced byGlaxoSmithKline over the period 2006-12 and how this compares togeneric risk across the Big Pharma peer set CHAPTER 1 EXECUTIVE SUMMARY 2 Key findings 2 Historical and forecast ethical sales performance 3 Therapeutic strategy 5 Launch and expiry outlook 10 Externalization, geographic and molecule type strategies 13 Externalization strategy 14 Geographic strategy 15 Molecule type strategy 16 SWOT analysis 17 Strengths 17 Weaknesses 18 Opportunities 19 Threats 21 CHAPTER 2 CORPORATE HISTORY 24 Key findings 24 Background 25 M&A history 25 Wellcome 25 Glaxo 25 Glaxo Wellcome 26 Beecham 26 Smith Kline 26 SmithKline Beecham 27 Key historical drug launches by component GSK companies 28 M&A strategy 29 R&D overview 32 Current corporate structure 34 CHAPTER 3 HISTORICAL PERFORMANCE 35 Key findings 35 Introduction 36 Revenue and growth rate analysis, 2001-06 36 Revenue and growth rate vs. peer set 37 Product analysis, 2001-06 39 Growth drivers 39 Seretide/Advair 39 Avandia 40 Flixotide 40 Lamictal 40 Growth resistors 40 Seroxat 40 Augmentin 41 Serevent 41 Operating revenue and cost analysis, 2001-06 42 Operating revenue/cost analysis 43 CHAPTER 4 FORECAST PERFORMANCE 45 Key findings 45 Introduction 46 Revenue and growth rate, 2006-12 46 Product analysis, 2006-12 48 Growth drivers 53 Tykerb 53 Cervarix 54 Growth resistors 54 Seretide/Advair 54 Avandia 55 Wellbutrin 55 Zofran 56 Imigran 56 Therapy area analysis, 2006-12 58 Oncology 61 Urology & sexual health 61 Infectious disease 62 Respiratory 62 CNS 62 Endocrine, metabolic & genetic disorders 63 Therapy area focus 63 Launches and expiries analysis, 2006-12 68 Launch portfolio 69 Core portfolio 72 Expiry portfolio 74 Launch/core/expiry configuration 77 Externalization analysis, 2006-12 81 Geographic analysis, 2006-12 86 Molecule type analysis, 2006-12 89 CHAPTER 5 KEY PRODUCTS AND COMPETITORS 95 Key findings 95 Overview 96 Respiratory 97 Seretide/Advair 97 Overview 97 Sales forecast 98 Newsflow 98 Oncology 103 Tykerb 103 Overview 103 Sales forecast 104 Newsflow 104 Cervarix 107 Overview 107 Sales forecast 108 Newsflow 108 Zofran 112 Overview 112 Sales forecast 113 Newsflow 113 CNS 115 Lamictal 115 Overview 115 Sales forecast 116 Newsflow 116 Gepirone ER 119 Overview 119 Sales forecast 120 Newsflow 120 Trexima 122 Overview 122 Sales forecast 123 Newsflow 124 Wellbutrin 126 Overview 126 Sales forecast 127 Newsflow 127 Imigran 130 Overview 130 Sales forecast 131 Newsflow 131 Endocrine, metabolic & genetic disorders 133 Avandia 133 Overview 133 Sales forecast 134 Newsflow 135 Infectious disease 139 Rotarix 139 Overview 139 Sales forecast 140 Newsflow 140 CHAPTER 6 APPENDIX 143 IMS vs. company-reported data reconciliation 143 References 146 Datamonitor reports 146 Abbreviations 146 Exchange rates 147 List of Tables Table 1: Peer set overview 37 Table 2: Operating revenue/cost analysis ($m), 2001-06 42 Table 3: Operating cost ratio analysis (% of total revenues),2001-06 43 Table 4: Product portfolio overview, sales ($m), 2006-12 48 Table 5: Therapy area overview, sales ($m), 2006-12 58 Table 6: Launch portfolio overview, sales ($m), 2006-12 69 Table 7: Core portfolio overview, sales ($m), 2006-12 73 Table 8: Expiry portfolio overview, sales ($m), 2006-12 75 Table 9: Externally developed portfolio ($m), 2006-12 81 Table 10: Molecule type overview, sales ($m), 2006-12 89 Table 11: Key products overview 96 Table 12: Seretide/Advair: overview 97 Table 13: Seretide/Advair: sales forecast ($m), 2006-12 98 Table 14: Seretide/Advair: news flow 98 Table 15: Tykerb: overview 103 Table 16: Tykerb: sales forecast ($m), 2006-12 104 Table 17: Tykerb: news flow 104 Table 18: Cervarix: overview 107 Table 19: Cervarix: sales forecast ($m), 2006-12 108 Table 20: Cervarix: news flow 108 Table 21: Zofran: overview 112 Table 22: Zofran: sales forecast ($m), 2006-12 113 Table 23: Zofran: news flow 113 Table 24: Lamictal: overview 115 Table 25: Lamictal: sales forecast ($m), 2006-12 116 Table 26: Lamictal: news flow 116 Table 27: Gepirone ER: overview 119 Table 28: Gepirone ER: sales forecast ($m), 2006-12 120 Table 29: Gepirone ER: news flow 120 Table 30: Trexima: overview 122 Table 31: Trexima: sales forecast ($m), 2006-12 123 Table 32: Trexima: news flow 124 Table 33: Wellbutrin: overview 126 Table 34: Wellbutrin: sales forecast ($m), 2006-12 127 Table 35: Wellbutrin: news flow 127 Table 36: Imigran: overview 130 Table 37: Imigran: sales forecast ($m), 2006-12 131 Table 38: Imigran: news flow 131 Table 39: Avandia: overview 133 Table 40: Avandia: sales forecast ($m), 2006-12 134 Table 41: Avandia: news flow 135 Table 42: Rotarix: overview 139 Table 43: Rotarix: sales forecast ($m), 2006-12 140 Table 44: Rotarix: news flow 140 Table 45: Exchange rates, 2006 147 List of Figures Figure 1: Historical and forecast ethical sales performance (%CAGR), GSK and Big Pharma peer set 4 Figure 2: Therapeutic focus vs. Big Pharma peer set (%), 2006 6 Figure 3: Launch, core and expiry, absolute sales growth, 2006-12

(sales as % of 2006 sales), GSK 10 Figure 4: Launch, core and expiry, absolute sales growth, 2006-12

(sales as % of 2006 sales), peer set 12 Figure 5: Molecule type, externalization and geographic marketdependency (%) vs. peer set, 2006 13 Figure 6: Molecule type, externalization and geographic marketdependency (%) vs. peer set, 2012 14 Figure 7: SWOT analysis of GSK 17 Figure 8: M&A/divestment history 27 Figure 9: Revenue & growth rate (ethical sales) ($m), 2001-06 36 Figure 10: Ethical revenue ($m) and growth rate (%) vs. peer set,2001-06 38 Figure 11: Growth drivers/resistor products of historical revenueperformance ($m), 2001-06 39 Figure 12: Operating revenue/cost analysis ($m), 2001-06 43 Figure 13: Operating cost ratio analysis (% of total revenues),2001-06 44 Figure 14: Ethical revenue ($m) and growth rate (%), 2006-12 46 Figure 15: Top five products by sales ($m), 2006 51 Figure 16: Top five products by sales ($m), 2012 52 Figure 17: Growth drivers and resistors by product, 2006-12 53 Figure 18: Key strategic products, sales ($m), 2006-12 57 Figure 19: Ethical sales by therapy area ($m), 2006-12 59 Figure 20: Growth drivers and resistors by therapy area (%),2006-12 61 Figure 21: Ethical sales by therapy area ($m), 2006-12 63 Figure 22: Therapy area focus compared with peer set (% totalethical sales), 2006 64 Figure 23: Therapy area focus compared with peer set (% totalethical sales), 2012 67 Figure 24: Launch schedule, sales ($m), 2006-12 71 Figure 25: Core products sales growth ($m), 2006-12 74 Figure 26: Expiry schedule, sales ($m), 2006-12 76 Figure 27: Launch, core and expiry, sales ($m), 2006-12 78 Figure 28: Launch, core and expiry, absolute sales growth, 2006-12

(sales as % of 2006 sales), GlaxoSmithKline 79 Figure 29: Launch, core and expiry, absolute sales growth, 2006-12

(sales as % of 2006 sales), peer set 80 Figure 30: Externalization dependency, sales ($m), 2006-12 82 Figure 31: Growth drivers and resistors, externally vs. internallydiscovered products, sales ($m), 2006-12 83 Figure 32: Externalization dependency vs. peer set, % total sales,2006 84 Figure 33: Externalization dependency vs. peer set, % total sales,2012 85 Figure 34: Geographical sales breakdown ($m), 2006-12 86 Figure 35: Growth drivers and resistors by geography, sales ($m),2006-12 87 Figure 36: US dependency vs. peer set, % total sales, 2006 88 Figure 37: US dependency vs. peer set, % total sales, 2012 89 Figure 38: Growth drivers and resistors by molecule type, sales

($m), 2006-12 91 Figure 39: Molecule type sales breakdown ($m), 2006-12 92 Figure 40: Biologics dependency vs. peer set, % total sales, 200693 Figure 41: Biologics dependency vs. peer set, % total sales, 201294 Figure 42: IMS vs. company-reported ethical sales discrepancy

($m), 2006 144 Figure 43: IMS vs. company-reported ethical sales forecast growthrates (%), 2006-12 145 More market research reports? Go to http://www.reportlinker.comReportlinkerNicolasnbo@reportlinker.com+33 4 37 65 17 03.Copyright Business Wire 2007